Anup Marda compensation by year
Cabaletta Bio Summary Compensation Table · the one fiscal year held| Component | FY2019 |
|---|---|
| Salary | $303,189 |
| Bonus | $60,000 |
| Stock awards | $0 |
| Option awards | $980,437 |
| Non-equity incentive | $185,008 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $1,528,634 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cabaletta Bio, Inc. DEF 14A filed April 23, 2020, accession 0001193125-20-115863, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cabaletta Bio, Inc. filed document, accession 0001193125-20-115863. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 139,282 | — | $4.23 |
| Option | 66,463 | — | $11.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cabaletta Bio, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
18 Form 4 lines since the FY2019 proxy (filed April 23, 2020)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-02 | Grant or award derivative | — | 225,000 | $0.00 | 225,000 |
| 2025-05-19 | Grant or award derivative | — | 66,463 | $0.00 | 66,463 |
| 2025-05-19 | Grant or award derivative | — | 100,000 | $0.00 | 100,000 |
| 2025-05-19 | Grant or award derivative | — | 135,000 | $0.00 | 135,000 |
| 2025-05-19 | Grant or award derivative | — | 130,000 | $0.00 | 130,000 |
| 2025-05-19 | Grant or award derivative | — | 139,282 | $0.00 | 139,282 |
| 2025-05-19 | Disposition to the issuer derivative | — | 24,711 | $0.00 | 0 |
| 2025-05-19 | Disposition to the issuer derivative | — | 139,282 | $0.00 | 0 |
The 8 most recent of 18 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Cabaletta Bio’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Anup Marda · this page | Chief Financial Officer | $1,528,634 |
| Steven Nichtberger | President and Chief Executive Officer | $1,499,000 |
| Gwendolyn Binder | Executive Vice President, Science and Technology | $1,221,083 |
The full Cabaletta Bio compensation record
free company briefThis page is one person within Cabaletta Bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cabaletta Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.